Pre- and post-therapy nodal status equally affects survival of patients with oesophageal squamous cell carcinoma receiving preoperative chemoradiation

Oncology Reports

Volumn 23, Issue 5, 2010, Pages 1331-1337

  Miyata, Hiroshi ^a   Yamasaki, Makoto ^a   Takiguchi, Shuji ^a   Nakajima, Kiyokazu ^a   Fujiwara, Yoshiyuki ^a   Mori, Masaki ^a   Doki, Yuichiro ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemoradiotherapy; Lymph node status; Oesophageal cancer

Indexed keywords

CISPLATIN; FLUOROURACIL;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURGERY; CANCER SURVIVAL; CONTINUOUS INFUSION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; CISPLATIN; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIERS ESTIMATE; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 77950819424     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000768     Document Type: Article

References (47)

1. Earlam R and Cunha-Melo JR: Oesophageal squamous cell carcinoma: I. A critical review of surgery. Br J Surg 67: 381-390, 1980. (Pubitemid 10059625)
2. Muller JM, Erasmi H, Stelzner M, Zieren U and Pichlmaier H: Surgical therapy of oesophageal carcinoma. Br J Surg 77: 845-857, 1990.
3. Skinner D: Surgical treatment for esophageal carcinoma. Semin Oncol 11: 136-143, 1984.
4. Roder JD, Busch R, Stein HJ, Fink U and Siewert JR: Ratio of invaded to removed lymph nodes as a predictor of survival in squamous cell carcinoma of the oesophagus. Br J Surg 81: 410-413, 1994.
5. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N and Hennessy TP: A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 335: 462-467, 1996.
6. Burmeister BH, Smithers BM, Gebski V, et al: Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol 6: 659-668, 2005.
7. Tepper J, Krasna MJ, Niedzwiecki D, et al: Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 26: 1086-1092, 2008.
8. Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J and Simes J; Australasian Gastro-Intestinal Trials Group: Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 8: 226-234, 2007.
9. Urschel JD and Vasan H: A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for respectable esophageal cancer. Am J Surg 185: 538-543, 2003.
10. Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A and Strawderman M: Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 19: 305-313, 2001.
11. Berger AC, Farma J, Scott WJ, et al: Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol 23: 4330-4337, 2005.
12. Rizk NP, Venkatraman E, Bains MS, et al: American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma. J Clin Oncol 25: 507-512, 2007.
13. Reynolds JV, Muldoon C, Hollywood D, et al: Long-term outcomes following neoadjuvant chemoradiotherapy for esophageal cancer. Ann Surg 245: 707-716, 2007.
14. Chirieac LR, Swisher SG, Ajani JA, et al: Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer 103: 1347-1355, 2005.
15. Schneider PM, Baldus SE, Metzger R, et al: Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer. Implication for response classification. Ann Surg 5: 684-692, 2005.
16. Brucher BLDM, Becker K, Lordick F, et al: The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas. Cancer 106: 2119-2127, 2006.
17. Altorki N, Kent M, Ferrara C and Port J: Three-Field lymph node dissection for squamous cell and adenocarcinoma of the esophagus. Ann Surg 236: 177-183, 2002.
18. Akiyama H, Tsurumaru M, Udagawa H and Kajiyama Y: Radical lymph node dissection for cancer of the thoracic esophagus. Ann Surg 220: 364-373, 1994. (Pubitemid 24313229)
19. Lerut T, DeKeyn P, Coosemsms W, van Raemdonck D, Scheys I and Le Saffre E: Surgical strategies in esophageal carcinoma with emphasis on radial lymphadenectomy. Ann Surg 216: 583-590, 1992.
20. Yano M, Takachi K, Doki Y, et al: Prognosis of patients who develop cervical lymph node recurrence following curative resection for thoracic esophageal cancer. Dis Esophagus 19: 73-77, 2006.
21. Lerut T, Flamen P, Ectors N, et al: Histopathologic validation of lymph node staging with FDG-PET scan in cancer of the esophagus and gastroesophageal junction: a prospective study based on primary surgery with extensive lymphadenectomy. Ann Surg 232: 743-752, 2000.
22. Makino T, Doki Y, Miyata H, et al: Use of (18)F-fluorodeoxyglucose- positron emission tomography to evaluate responses to neo-adjuvant chemotherapy for primary tumor and lymph node metastasis in esophageal squamous cell carcinoma. Surgery 144: 793-802, 2008.
23. Higuchi I, Yasuda T, Yano M, et al: Lack of fludeoxyglucose F 18 uptake in posttreatment positron emission tomography as a significant predictor of survival after subsequent surgery in multimodality treatment for patients with locally advanced esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg 136: 205-212, 2008.
24. Miyata H, Doki Y, Yasuda T, et al: Evaluation of clinical significance of 18F-fluorodeoxyglucose positron emission tomography in superficial squamous cell carcinomas of the thoracic esophagus. Dis Esophagus 21: 144-150, 2008.
25. Yano M, Yasuda T, Miyata H, Fujiwara Y, Takiguchi S and Monden M: Correlation between histological effects on the main tumors and nodal status after chemoradiotherapy for squamous cell carcinoma of the esophagus. J Surg Oncol 89: 244-250, 2005.
26. Kishi K, Doki Y, Miyata H, Yano M, Yasuda T and Monden M: Prediction of the response to chemoradiation and prognosis in oesophageal squamous cancer. Br J Surg 89: 597-603, 2002.
27. Miyata H, Doki Y, Shiozaki H, et al: CDC25B and p53 are independently implicated in radiation sensitivity for human esophageal cancers. Clin Cancer Res 6: 4859-4865, 2000.
28. Japanese Society for Esophageal Diseases: Guidelines for the Clinical and Pathologic Studies on Carcinoma of the Esophagus. 10th edition. Kanehara Syuppan, Tokyo, 2007.
29. Ohtsu A, Boku N, Muro K, et al: Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol 17: 2915-2921, 1999.
30. Mandard AM, Dalibard F, Mandard JC, et al: Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Cancer 73: 02686, 1994.
31. Chang F, Deere H, Mahadeva U and George S: Histopathologic examination and reporting of esophageal carcinomas following preoperative neoadjuvant therapy; Practical guidelines and current issues. Am J Clin Path 129: 252-262, 2008.
32. Peyre CG, Hagen JA, DeMeester SR, et al: Predicting systemic disease in patients with esophageal cancer after esophagectomy: a multinational study on the significance of the number of involved lymph nodes. Ann Surg 248: 979-985, 2008.
33. Gaca JG, Petersen RP, Peterson BL, et al: Pathologic nodal status predicts disease-free survival after neoadjuvant chemoradiation for gastroesophageal junction carcinoma. Ann Surg Oncol 13: 340-346, 2006.
34. Gu Y, Swisher SG, Ajani JA, et al: The number of lymph nodes with metastasis predicts survival in patients with esophageal or esphagogastric junction adenocarcinoma who receive preoperative chemoradiation. Cancer 106: 1017-1025, 2006.
35. Rizk NP, Seshan VE, Bains MS, Ilson DH, Minsky BD, Tang L and Rusch VW: Prognostic factors after combined modality treatment of squamous cell carcinoma of the esophagus. J Thorac Oncol 2: 1117-1123, 2007.
36. Rice TW, Blackstone EH, Adelstein DJ, et al: N1 esophageal carcinoma: the importance of staging and downstaging. J Thorac Oncol 121: 454-464, 2001.
37. Kelly S, Harris KM, Berry E, et al: A systematic review of the staging performance of endoscopic ultrasound in gastrooesophageal carcinoma. Gut 49: 534-539, 2001.
38. Botet JF, Lightdale CJ, Zauber AG, Gerdes H, Urmacher C and Brennan MF: Preoperative staging of esophageal cancer: comparison of endoscopic US and dynamic CT. Radiology 181: 419-425, 1991.
39. Tio TL, Coene PP, Luiken GJ and Tytgat GN: Endosonography in the clinical staging of esophagogastric carcinoma. Gastrointest Endosc 36: S2-S10, 1990.
40. Greenberg J, Durkin M, van Drunen M and Aranha GV: Computed tomography or endoscopic ultrasonography in preoperative staging of gastric and esophageal tumors. Surgery 116: 696-701, 1994.
41. Vickers J and Alderson D: Oesophageal cancer staging using endoscopic ultrasonography. Br J Surg 85: 994-998, 1998.
42. Van Vliet EP, Eijkemans MJ, Poley JW, Steyerberg EW, Kuipers EJ and Siersema PD: Staging of esophageal carcinoma in a low-volume EUS center compared with reported results from high-volume centers. Gastrointest Endosc 63: 938-947, 2006.
43. Kato H, Kuwano H, Nakajima M, et al: Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma. Cancer 94: 921-928, 2002.
44. Flamen P, Lerut A, van Cutsem E, et al: Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol 18: 3202-3210, 2000.
45. Luketich JD, Schauer P, Landreneau R, et al: Minimally invasive surgical staging is superior to endoscopic ultrasound in detecting lymph node metastases in esophageal cancer. J Thorac Cardiovasc Surg 114: 817-821, 1997.
46. Stahl M, Stuschke M, Lehmann N, et al: Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 23: 2310-2317, 2005.
47. Bedenne L, Michel P, Bouche O, et al: Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 25: 1160-1168, 2007.